Published in

BioMed Central, BMC Cancer, 1(14), 2014

DOI: 10.1186/1471-2407-14-828

Links

Tools

Export citation

Search in Google Scholar

Emerging markers of cachexia predict survival in cancer patients

Journal article published in 2014 by Patrizia Mondello, Antonio Lacquaniti, Stefania Mondello, Davide Bolignano ORCID, Vincenzo Pitini, Carmela Aloisi, Michele Buemi
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Background Cachexia may occur in 40% of cancer patients, representing the major cause of death in more than 20% of them. The aim of this study was to investigate the role of leptin, ghrelin and obestatin as diagnostic and predictive markers of cachexia in oncologic patients. Their impact on patient survival was also evaluated. Methods 140 adults with different cancer diagnoses were recruited. Thirty healthy volunteers served as control. Serum ghrelin, obestatin and leptin were tested at baseline and after a follow-up period of 18 months. Results Ghrelin levels were significantly higher in cancer patients than in healthy subjects (573.31 ± 130 vs 320.20 ± 66.48 ng/ml, p